Bicycle Therapeutics Limited Stock Price, News & Analysis

Bicycle Therapeutics (NASDAQ: BCYC) announced upcoming presentations of data for zelenectide pevedotin at the 2024 San Antonio Breast Cancer Symposium. The company will present findings showing enhanced anti-tumor activity in triple-negative breast cancer patients with NECTIN4 gene amplification.

Additionally, Bicycle will announce topline data for zelenectide pevedotin plus pembrolizumab combination in first-line metastatic urothelial cancer patients, and monotherapy results in non-small cell lung cancer patients. The poster presentation, led by Dr. Niklas Klümper from University Hospital Bonn, is scheduled for December 12. A conference call to discuss these updates will be held on December 13.

Bicycle Therapeutics (NASDAQ: BCYC), a pharmaceutical company developing innovative therapeutics using its proprietary bicyclic peptide technology, has announced its participation in the upcoming Jefferies London Healthcare Conference. The company's management will engage in a fireside chat on November 19, 2024, at 10:30 a.m. GMT. Investors and interested parties can access a live webcast of the presentation through the company's website, with a replay available after the event.

Bicycle Therapeutics (NASDAQ: BCYC) announced that its Compensation Committee granted inducement awards to twelve new employees on November 1, 2024. The awards consist of non-qualified share options to purchase 56,700 ordinary shares under the company's 2024 Inducement Plan. The options have an exercise price of $23.44 per share, based on the closing price on October 31, 2024. The options will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months, subject to continued employment.

Bicycle Therapeutics (NASDAQ: BCYC) reported Q3 2024 financial results and business updates. Key highlights include a 45% overall response rate for both zelenectide pevedotin and BT5528 in metastatic urothelial cancer trials. The company's cash position stands at $890.9 million as of September 30, 2024, with runway extending into 2H 2027. Q3 showed a net loss of $50.8 million, or $(0.74) per share. R&D expenses increased to $48.3 million, up from $39.9 million in Q3 2023, while G&A expenses rose to $18.3 million from $16.3 million year-over-year.

Bicycle Therapeutics (NASDAQ: BCYC) presented the first human imaging data at EANM 2024 Congress, validating MT1-MMP as a novel cancer treatment target. The data came from a case study of a 65-year-old male with pulmonary adenocarcinoma, where the Bicycle Radionuclide Conjugates (BRC®) demonstrated positive imaging properties and specific tumor uptake. The company also presented preclinical data showing optimized biodistribution of BRCs with high tumor uptake and reduced kidney retention.

The company announced EphA2 as its second BRC target and plans to collaborate with Eckert & Ziegler for radioisotope supply and BRC development.

Bicycle Therapeutics (NASDAQ: BCYC) will present data on its Bicycle Radionuclide Conjugates (BRC®) at the European Association of Nuclear Medicine (EANM) 2024 Congress in Hamburg, Germany, from October 19-23. The German Cancer Consortium (DKTK) will reveal the first human imaging data for a BRC targeting MT1-MMP, a tumor antigen common in many cancers, on October 22. Additionally, Bicycle Therapeutics will share an e-poster on BRCs for radioisotope delivery to solid tumors. A conference call and webcast will be held on October 23 at 8 a.m. ET to discuss the data and the company's radiopharmaceutical strategy. The call can be accessed by dialing +1-833-816-1408 (U.S.) or +1-412-317-0501 (international) and requesting the Bicycle Therapeutics call. A live webcast and replay will be available on the company's website.

Bicycle Therapeutics (NASDAQ: BCYC) has announced the granting of inducement awards to eight new employees on October 1, 2024. These awards consist of non-qualified share options to purchase a total of 47,600 ordinary shares. The options were granted under the company's 2024 Inducement Plan and approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Each option has an exercise price of $22.63 per share, which was Bicycle Therapeutics' closing trading price on September 30, 2024. The options will vest over four years, with 25% vesting on the one-year anniversary of the vesting commencement date and the remaining 75% vesting monthly over the following 36 months, subject to continued employment.

Bicycle Therapeutics (NASDAQ: BCYC) presented updated clinical results for its oncology pipeline at ESMO Congress 2024. Key highlights include:

1. Zelenectide pevedotin (Nectin-4 targeting) showed a 45% overall response rate (ORR) in metastatic urothelial cancer (mUC) with 11.1 months median duration of response.

2. BT5528 (EphA2-targeting) demonstrated a 45% ORR in mUC at 6.5 mg/m2 every two weeks.

3. Both drugs showed low frequency and severity of treatment-related peripheral neuropathy.

4. BT7480 (Nectin-4 targeted CD137 agonist) showed a favorable safety profile and preliminary antitumor activity in advanced solid tumors.

These results support the potential of Bicycle's technology platform to create differentiated medicines for cancer treatment.

Bicycle Therapeutics plc (NASDAQ: BCYC) has announced the granting of inducement awards to seven new employees on September 3, 2024. These awards consist of non-qualified share options to purchase a total of 29,500 ordinary shares. The options were granted under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

Key details of the options include:

• Exercise price: $21.50 per share (based on the closing trading price on August 30, 2024)
• Vesting period: 4 years (25% after one year, remaining balance monthly over 36 months)
• Subject to continued employment with the company

These awards are designed to serve as an inducement for new employees joining Bicycle Therapeutics.